Clinical trial
Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate…
NCT00031187 · Seagen Inc., Industry · Completed
Key facts
| NCT number | NCT00031187 |
|---|---|
| Title | Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer |
| Official title | Phase II Study of SGN-15 (cBR96 - Doxorubicin Immunoconjugate) Combined With Taxotere in Patients With Hormone Refractory Prostate Carcinoma |
| Lead sponsor | Seagen Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Drug |
| Interventions | SGN-15 (cBR96-doxorubicin immunoconjugate), Taxotere (docetaxel) |
| Enrollment | 160 |
| Start date | Oct 1, 2000 |
| Completion | Jul 1, 2003 |
| First posted | Feb 28, 2002 |
| Last update posted | Oct 24, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: